Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $1.33M |
| EBITDA | $-24.07M |
| Operating Margin | 0.00% |
| Return on Equity | -345.30% |
| Return on Assets | -65.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.47 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 23.75 |
| EV/Revenue | 0.0421 |
| EV/EBITDA | -0.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $19.34M |
| Float | $19.34M |
| % Insiders | 1.24% |
| % Institutions | 3.61% |
Volatility is currently expanding
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications.
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KALA and any ticker you trade — then tracks every position and per-strategy win rate.
